Brimonidine Tartrate Solution/ Drops
NDC 42571-419
Product Information
Brimonidine Tartrate is a ANDA-approved product labeled by Micro Labs Limited. This medication is used to treat open-angle glaucoma or high fluid pressure in the eye. It is supplied as a solution/ drops for ophthalmic administration. This product entry covers the primary NDC 42571-419 and 3 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 42571-419?
What are the uses of this product?
What are Active Ingredients of this product?
- BRIMONIDINE TARTRATE 2 mg/mL - A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- BRIMONIDINE TARTRATE (UNII: 4S9CL2DY2H)
- BRIMONIDINE (UNII: E6GNX3HHTE) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- BENZALKONIUM CHLORIDE (UNII: F5UM2KM3W7)
- CITRIC ACID MONOHYDRATE (UNII: 2968PHW8QP)
- POLYVINYL ALCOHOL (UNII: 532B59J990)
- SODIUM CHLORIDE (UNII: 451W47IQ8X)
- SODIUM CITRATE (UNII: 1Q73Q2JULR)
- WATER (UNII: 059QF0KO0R)
- HYDROCHLORIC ACID (UNII: QTT17582CB)
- SODIUM HYDROXIDE (UNII: 55X04QC32I)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 861200 - brimonidine tartrate 0.2 % Ophthalmic Solution
- RxCUI: 861200 - brimonidine tartrate 2 MG/ML Ophthalmic Solution
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.